Terms: = Thyroid cancer AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132
11 results:
1. PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating keap1 and inhibiting ferroptosis.
Wang Z; Li R; Hou N; Zhang J; Wang T; Fan P; Ji C; Zhang B; Liu L; Wang Y; Kong J; Yao Q; Duan J; Zhao G; Ling R; Zhang J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37380368
[TBL] [Abstract] [Full Text] [Related]
2. TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection.
Miyagawa-Hayashino A; Okada S; Takeda-Miyata N; Takashima Y; Yamada T; Takemura Y; Uchino J; Inoue M; Takayama K; Konishi E
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):313-320. PubMed ID: 33031101
[TBL] [Abstract] [Full Text] [Related]
3. FosB recruits KAT5 to potentiate the growth and metastasis of papillary thyroid cancer in a DPP4-dependent manner.
Du J; Fu L; Ji F; Wang C; Liu S; Qiu X
Life Sci; 2020 Oct; 259():118374. PubMed ID: 32891613
[TBL] [Abstract] [Full Text] [Related]
4. Fabrication and characterization of solid lipid nano-formulation of astraxanthin against DMBA-induced breast cancer via Nrf-2-keap1 and NF-kB and mTOR/Maf-1/PTEN pathway.
Sun T; Gao J; Han D; Shi H; Liu X
Drug Deliv; 2019 Dec; 26(1):975-988. PubMed ID: 31556759
[TBL] [Abstract] [Full Text] [Related]
5. Rare and common genetic variations in the keap1/Nrf2 antioxidant response pathway impact thyroglobulin gene expression and circulating levels, respectively.
Matana A; Ziros PG; Chartoumpekis DV; Renaud CO; PolaĊĦek O; Hayward C; Zemunik T; Sykiotis GP
Biochem Pharmacol; 2020 Mar; 173():113605. PubMed ID: 31421134
[TBL] [Abstract] [Full Text] [Related]
6. Impact of Antioxidant Natural Compounds on the thyroid Gland and Implication of the keap1/Nrf2 Signaling Pathway.
Paunkov A; Chartoumpekis DV; Ziros PG; Chondrogianni N; Kensler TW; Sykiotis GP
Curr Pharm Des; 2019; 25(16):1828-1846. PubMed ID: 31267862
[TBL] [Abstract] [Full Text] [Related]
7. Oncogenic mutations in keap1 disturbing inhibitory Nrf2-keap1 interaction: Activation of antioxidative pathway in papillary thyroid carcinoma.
Danilovic DLS; de Mello ES; Frazzato EST; Wakamatsu A; de Lima Jorge AA; Hoff AO; Marui S
Head Neck; 2018 Jun; 40(6):1271-1278. PubMed ID: 29469959
[TBL] [Abstract] [Full Text] [Related]
8. An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.
Cardnell RJ; Behrens C; Diao L; Fan Y; Tang X; Tong P; Minna JD; Mills GB; Heymach JV; Wistuba II; Wang J; Byers LA
Clin Cancer Res; 2015 Aug; 21(15):3480-91. PubMed ID: 25878335
[TBL] [Abstract] [Full Text] [Related]
9. Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor keap1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer.
Martinez VD; Vucic EA; Pikor LA; Thu KL; Hubaux R; Lam WL
Mol Cancer; 2013 Oct; 12(1):124. PubMed ID: 24138990
[TBL] [Abstract] [Full Text] [Related]
10. Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells.
Ziros PG; Manolakou SD; Habeos IG; Lilis I; Chartoumpekis DV; Koika V; Soares P; Kyriazopoulou VE; Scopa CD; Papachristou DJ; Sykiotis GP
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1422-7. PubMed ID: 23766517
[TBL] [Abstract] [Full Text] [Related]
11. Trends in the clinical characteristics of patients with papillary thyroid carcinoma in Taiwan.
Lin JD; Chao TC; Sun JH; Ho C; Weng HF
Oncology; 2000 May; 58(4):280-5. PubMed ID: 10838492
[TBL] [Abstract] [Full Text] [Related]
